• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

成人局部晚期或转移性非小细胞肺癌患者的靶向治疗的临床疗效和成本效益：系统评价。

Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review.

机构信息

Department of Medical Oncology, National Cancer Institute, Aviano (PN), Italy.

出版信息

Curr Cancer Drug Targets. 2018;18(5):405-409. doi: 10.2174/1568009617666170206112408.

DOI:10.2174/1568009617666170206112408
PMID:28176647
Abstract

Treatment for advanced non-small cell lung cancer has changed in the last two decades, with many new drugs, mostly target agents, included in the algorithm, improvement of progression free survival and overall survival, but also higher costs for health systems or health insurances. Herein, we analyze the clinical effectiveness of target therapies for non-small cell lung cancer, according to their clinically meaningful outcome criteria and their cost impact.

摘要

在过去的二十年中，晚期非小细胞肺癌的治疗发生了变化，许多新的药物，主要是靶向药物，被纳入了治疗方案中，改善了无进展生存期和总生存期，但也增加了卫生系统或健康保险的成本。在此，我们根据有临床意义的疗效评价标准和成本影响，分析了非小细胞肺癌的靶向治疗的临床疗效。

相似文献

1
Clinical Effectiveness and Cost-effectiveness of Target Therapies for Adult Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer: A Systematic Review.成人局部晚期或转移性非小细胞肺癌患者的靶向治疗的临床疗效和成本效益：系统评价。
Curr Cancer Drug Targets. 2018;18(5):405-409. doi: 10.2174/1568009617666170206112408.
2
Cost-Effectiveness and Value of Information of Erlotinib, Afatinib, and Cisplatin-Pemetrexed for First-Line Treatment of Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer in the United States.厄洛替尼、阿法替尼和顺铂-培美曲塞用于美国晚期表皮生长因子受体（EGFR）突变阳性非小细胞肺癌一线治疗的成本效益和信息价值
Value Health. 2015 Sep;18(6):774-82. doi: 10.1016/j.jval.2015.04.008. Epub 2015 Jun 22.
3
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer.一项关于一线化疗治疗局部晚期或转移性非小细胞肺癌成人患者的临床疗效的系统评价。
Thorax. 2015 Apr;70(4):359-67. doi: 10.1136/thoraxjnl-2014-205914. Epub 2015 Feb 6.
4
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).针对转移性非小细胞肺癌（NSCLC）的靶向治疗的成本效益的系统评价。
BMC Pulm Med. 2014 Dec 4;14:192. doi: 10.1186/1471-2466-14-192.
5
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.吉非替尼用于局部晚期或转移性非小细胞肺癌的一线治疗。
Health Technol Assess. 2010 Oct;14(Suppl. 2):71-9. doi: 10.3310/hta14suppl2/10.
6
Cost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care system.顺铂和培美曲塞化疗后继续培美曲塞维持治疗晚期非鳞状非小细胞肺癌的成本效益：来自中国医疗保健系统视角的评估。
Clin Ther. 2013 Jan;35(1):54-65. doi: 10.1016/j.clinthera.2012.12.013.
7
Real-World Treatment Patterns, Overall Survival, and Occurrence and Costs of Adverse Events Associated With Second-Line Therapies for Medicare Patients With Advanced Non-Small-Cell Lung Cancer.医疗保险晚期非小细胞肺癌患者二线治疗的真实世界治疗模式、总生存及不良事件的发生和成本。
Clin Lung Cancer. 2018 Sep;19(5):e783-e799. doi: 10.1016/j.cllc.2018.05.016. Epub 2018 Jun 6.
8
Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer.转移性非小细胞肺癌化疗干预的决策框架
J Natl Cancer Inst. 2000 Aug 16;92(16):1321-9. doi: 10.1093/jnci/92.16.1321.
9
[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].[吉非替尼治疗表皮生长因子受体（EGFR）突变的晚期非小细胞肺癌患者：成本效益分析]
Vopr Onkol. 2015;61(4):676-80.
10
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.在中国，吉非替尼、埃克替尼和培美曲塞为基础的化疗作为晚期非小细胞肺癌一线治疗的成本效益分析
Oncotarget. 2017 Feb 7;8(6):9996-10006. doi: 10.18632/oncotarget.14310.

引用本文的文献

1
Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.癌症相关医疗保健的经济学研究：综述文献概述
J Natl Cancer Inst Monogr. 2022 Jul 5;2022(59):12-20. doi: 10.1093/jncimonographs/lgac011.
2
The effect of itraconazole on the clinical outcomes of patients with advanced non-small cell lung cancer receiving platinum-based chemotherapy: a randomized controlled study.伊曲康唑对接受铂类化疗的晚期非小细胞肺癌患者临床结局的影响：一项随机对照研究。
Med Oncol. 2021 Feb 9;38(3):23. doi: 10.1007/s12032-021-01475-0.
3
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab.
在接受纳武单抗PD-1免疫检查点阻断治疗的转移性非小细胞肺癌患者中，早期血液中针对核抗原和平滑肌抗原的自身抗体升高预示着生存期延长和自身免疫。
Mol Clin Oncol. 2019 Jul;11(1):81-90. doi: 10.3892/mco.2019.1859. Epub 2019 May 16.
4
Preoperative anemia as a prognostic factor in patients with lung cancer: a systematic review and meta-analysis of epidemiological studies.术前贫血作为肺癌患者的一个预后因素：一项关于流行病学研究的系统评价和荟萃分析
J Cancer. 2019 May 12;10(9):2047-2056. doi: 10.7150/jca.29410. eCollection 2019.